SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
How the UK’s rollback of banking regulations could risk another financial crisis 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
U.S. Banks Report Strong Q4 Profits Amid Investment Banking Surge 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Wall Street Rebounds as Investors Eye Tariff Uncertainty, Jobs Report 
Gold Prices Rise as Markets Await Trump’s Policy Announcements 
U.S. Stock Futures Rise as Trump Takes Office, Corporate Earnings Awaited 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Infosys Shares Drop Amid Earnings Quality Concerns 
China’s Growth Faces Structural Challenges Amid Doubts Over Data 
Do investment tax breaks work? A new study finds the evidence is ‘mixed at best’ 
Instagram Outage Disrupts Thousands of U.S. Users 
Insignia Financial Shares Hit 3-Year High Amid Bain and CC Capital Bidding War 
Apple Downgraded by Jefferies Amid Weak iPhone Sales and AI Concerns 
Samsung Biologics would invest 1.74 trillion in building a massive fourth plant in Songdo, Incheon, that would employ 1,800 new employees by 2023 and produce 256,000 liters of drug substances in a single generation.
According to CEO Kim Tae-han, the construction will increase its output at its Songdo complex 1 to 620,000 liters, accounting for 30 percent of the world’s contract manufacturing market.
Samsung Biologics currently has a combined 364,000-liter capacity at its three existing plants, with one of those producing 180,000 liters and touted as having the world’s largest single-plant capacity.
Construction of the fourth plant will take 36 months and poised to create 27,000 jobs and bring in 5.6 trillion won in economic benefits.
Plant 4 will be a hybrid that has both stainless steel and single-use disposable bioreactors.
With speed being of critical significance in the biologics market, the new plant will be a game-changer.
It would provide a one-stop service comprising of cell line development and the manufacturing of clinical samples, active pharmaceutical ingredients, drug substances, and fill-and-finish drug products.
The one-stop service would dramatically reduce the time spent on commercializing a drug.
